Important note: Information in this article was accurate in December 2003. The state of the art may have changed since the publication date. |
AIDSWEEKLY Plus; Monday, December 22, 2003
Staff Medical Writers
In a recent study, scientists in India "investigated the safety, tolerability and effectiveness of locally produced generic highly active antiretroviral therapy (HAART) regimens with a chart review conducted at YRG CARE, a tertiary HIV referral center in India."
"A total of 333 patients had been on Indian-manufactured generic HAART for at least 3 months," according to N. Kumarasamy and coauthors working at the YRG Centre for AIDS Research and Education in Madras.
"In this cohort, generic HAART was safe, well tolerated and effective at increasing CD4 T-lymphocyte counts in patients with advanced HIV, comparable to the experience with proprietary HAART," the researchers concluded.
Kumarasamy and colleagues published their study in AIDS (The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS. 2003 Oct 17;17(15):2267-9.
For more information, contact N. Kumarasamy, YRG Centre for AIDS Research and Education, Madras, Tamil Nadu, India.
Publisher contact information for the journal AIDS is: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA.
The information in this article comes under the major subject areas of AIDS & HIV and Virology.
This article was prepared by AIDS Weekly editors from staff and other reports.
Reference
Kumarasamy N, Solomon S, Chaguturu SK, et al., "The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India", AIDS. 2003 Oct 17;17(15):2267-9.
PubMED Related articles Search
031222
AW031211
Copyright © 2003 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.